Dilaine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dilaine

Property Description
Active ingredient Minoxidil
Form Topical solution, topical foam
Pharmacological class Alopecia therapeutic agent, Potassium channel opener
Common use Promotion of hair growth in pattern hair loss
Origin Synthetic compound (Pyrimidine derivative)

What is Dilaine and Its Active Ingredient?

Dilaine is a proprietary medicinal preparation whose core component is the active ingredient Minoxidil, a synthetic compound that was originally developed for oral administration to manage high blood pressure. Minoxidil is chemically a pyrimidine derivative. While initially reserved for prescription use in its systemic form, the topical versions, such as Dilaine, are widely clinically recognized for their role in addressing male and female pattern hair loss.


What Pharmacological Class Does Dilaine Belong To?

The Minoxidil in Dilaine belongs to the pharmacological class of potassium channel openers and acts as a peripheral vasodilator. The medicine is formulated for topical (cutaneous) administration to the scalp, a key differentiation from its original systemic use, which localizes the effect where it is needed. Dilaine is supplied as a topical solution and a topical foam, utilizing specialized delivery vehicles for patient preference and targeted application.


What is the General Purpose of Dilaine?

The general purpose of Dilaine is to promote renewed hair growth and stabilize hair thinning through specific localized biological stimulation. Minoxidil achieves this by increasing microcirculation around the hair follicles and directly influencing the hair growth cycle to prolong the active growth phase. The application of this therapy is intended to counteract the progressive miniaturization of hair follicles, encouraging the development of thicker, more substantial hair shafts.

What side effects are possible with Dilaine?

The safety profile for Dilaine (topical Minoxidil) is documented by government regulatory bodies and outlines the officially reported adverse reactions, their frequencies, and specific safety constraints.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions are often localized, reflecting the product's method of administration. Reactions are formally classified by frequency in regulatory documents:

  • Very Common: Headache.
  • Common: Pruritus (itching), Dermatitis, Hypertrichosis (unwanted non-scalp hair growth), Peripheral Oedema (swelling of hands/feet), and Weight Increased.
  • Uncommon: Dizziness, Nausea, and Palpitations.
  • Not Known: Serious reactions like Angioedema and cardiovascular effects like Tachycardia (accelerated heart rate) and Hypotension.

Systemic Safety and Restrictions

While generally low, systemic absorption may lead to adverse effects related to the active ingredient's original cardiovascular action. Regulatory documents classify reactions by System-Organ-Class, noting effects in Skin and Subcutaneous Tissue Disorders and Cardiac Disorders.

Serious Adverse Reactions officially documented include severe cardiovascular effects (e.g., chest pain) and Angioedema, particularly following significant systemic exposure or accidental ingestion.

Safety-Related Restrictions include the constraint against applying the product to an inflamed, infected, or irritated scalp, as this increases systemic absorption risk. Use is not recommended for individuals under 18 years of age or in patients with pre-existing heart conditions. Furthermore, the label notes that a temporary increase in hair shedding may be an expected pattern occurring early in the course of treatment.

Overdose and Emergency Response

The regulatory description of Minoxidil (Dilaine) overdosage focuses on symptoms related to excessive systemic absorption, reflecting the drug's potent peripheral vasodilator activity. This can lead to severe cardiovascular and systemic effects, requiring immediate medical attention. Management of overdosage is strictly symptomatic and supportive, as no specific antidote is known.

Documented Overdose Manifestations
Cardiovascular/Neurological Signs Rapid heartbeat (tachycardia), chest pain, dizziness, faintness, headache, and lethargy.
Systemic/Fluid Signs Sudden, unexplained weight gain and swelling of the hands or feet (edema).

Accidental ingestion of the topical solution or excessive use leading to high systemic absorption is the key risk factor. Supportive measures include the use of diuretics for fluid retention, beta-adrenergic blocking agents for clinically significant tachycardia, and intravenous saline for symptomatic hypotension.

Regulator-Mandated Emergency Actions
Accidental Ingestion Seek professional assistance or contact a Poison Control Center immediately.
Systemic Symptoms Stop use and consult a doctor if chest pain, rapid heartbeat, faintness, dizziness, or swelling of the hands/feet occurs.

The product is not for use in babies or children and must be kept out of their reach, as accidental ingestion in a child has been reported to cause significant systemic hypotension and tachycardia.

Therapeutic Uses of Dilaine

The use of Dilaine (topical Minoxidil) is primarily focused on managing the signs and progression of Androgenetic Alopecia, which is the medical term for inherited pattern hair loss in both men and women. This medication is commonly used to help with renewed hair growth and assist with stabilizing hair thinning in patients with this condition.


Treating Chronic Pattern Hair Loss and Stabilization

This therapeutic area is commonly used across conditions characterized by long-term, gradual hair thinning associated with inherited patterns. The medication may be part of symptomatic management in these chronic contexts to assist with managing the symptoms of balding in long-term contexts. Dilaine provides support that supports the patient during difficult episodes by easing distress related to continuous thinning, by focusing on the visible appearance of hair density in the affected crown and vertex areas.

“This supportive approach contributes to the patient’s maintenance goals and helps ease the visible impact of thinning.”


Addressing Hair Miniaturization and Supporting Regrowth

Dilaine is applied in addressing the key symptom of progressive hair miniaturization, which results in finer, shorter hair that interferes with daily functioning. The therapeutic benefit is commonly used to help with renewed hair growth and may assist with improving the visual appearance of hair shafts. This use contributes to improved day-to-day comfort by lessening the visual impact of thinning and contributing to the perception of increased hair density. It is generally relevant in situations where patients experience mild-to-moderate patterned hair loss.

Quick Fact: Relief for Patterned Hair Thinning

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Dilaine (Topical Minoxidil)

Official regulatory documents define the population eligibility for Dilaine based on age, health status, and the type of hair loss.

Criteria Category Regulatory Status
Approved Age Adults 18 years and older only.
Pediatric Use Not recommended for children and adolescents under 18.
Geriatric Use Safety and effectiveness are not established in persons over 65.

Criteria Category Regulatory Status
Hair Loss Type Only for hereditary pattern hair loss. Prohibited for sudden, patchy, unexplained, or childbirth-related hair loss.
Scalp Condition Contraindicated if the scalp is red, inflamed, infected, irritated, painful, or shaved.
Hypersensitivity Contraindicated if there is a known allergy to minoxidil or any component in the formulation.

Criteria Category Regulatory Status
Pregnancy Not recommended for use in pregnant women.
Breastfeeding Not recommended for use, as the drug may be excreted in human milk.
Cardiovascular Risk Individuals with heart disease must consult a physician before use.
Gender/Concentration The 5% concentration is not for use by women due to the risk of unwanted facial hair growth.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Dilaine (Topical Minoxidil) based on governmental regulatory labeling. The interactions primarily concern exposure modification, interference with drug activation, and pharmacodynamic effects.


Documented Interaction Patterns

Substance Category
Exposure-Modifying Topical Products
Enzyme-Interfering Medicines
Systemic Vasodilatory Agents

Officially Noted Interaction Statements:

  • Co-administration of other topical products (including corticosteroids, retinoids, and petrolatum) on the same scalp area is formally restricted, as this practice is documented to increase the systemic absorption of Minoxidil.
  • Acetylsalicylic acid (low-dose aspirin) may reduce the clinical effectiveness of the product. This is due to interference with the sulfotransferase enzyme pathway necessary for Minoxidil’s activation.
  • Systemic peripheral vasodilators carry a documented theoretical risk of potentiating orthostatic hypotension due to the low-level systemic vasodilatory effects of absorbed Minoxidil.
  • Alcohol (Ethanol) consumption introduces a risk of additive hypotensive effects if systemic absorption occurs.
  • Patients with underlying cardiovascular dysfunction or fluid retention are noted to be at an increased risk for adverse systemic effects resulting from enhanced absorption when co-administered with exposure-modifying agents.

Regulatory Summary: The official interaction profile is structured around the risk of enhanced percutaneous absorption, which increases systemic exposure, and the clinically significant impact of agents like acetylsalicylic acid on the drug's essential enzymatic activation. No mandatory drug-drug administration separation times are documented in regulatory labels.

Mechanism of Action

How Dilaine Works

Dilaine (phenytoin) is a hydantoin derivative whose pharmacodynamic activity centers on modulating neuronal membrane excitability. The drug exerts its effect primarily through interaction with voltage-gated sodium channels (VGSCs) located on the neuronal cell surface.

Dilaine selectively binds to and stabilizes the VGSCs in their inactive, closed conformation following depolarization. This molecular engagement prolongs the channel's refractory period, specifically leading to rate-dependent inhibition of sustained, high-frequency action potentials. By modulating the channel's recovery kinetics, Dilaine limits the capacity of the neurons to fire repetitively. This modification of the ionic conductance reduces the excitability of the neuronal circuit.

The resulting physiological consequence is a change in the propagation and fidelity of excitatory impulses across the targeted neural network, fundamentally affecting the dynamics of signal transmission within the central nervous system.

Dosage and Administration Information

How to Use Dilaine

Dilaine (topical Minoxidil) is used according to specific administration protocols. The medicine is strictly for topical (cutaneous) use, applied directly to the affected areas of the scalp.

Official Dosing and Frequency

Feature Instruction
Administration Route Topical application to the scalp only.
Standard Unit Dose 1 milliliter (mL) of solution or half a capful of foam.
Maximum Daily Dose The total application must not exceed 2 mL of solution or 2 g of foam.
Frequency (Men) Twice daily (5% solution or 5% foam)
Frequency (Women) Twice daily (2% solution) or once daily (5% foam).

Application and Treatment Protocol

Application requires the hair and scalp to be completely dry prior to use. Following application, hands must be washed thoroughly and immediately. The product must be allowed to dry completely for at least two to four hours before engaging in activities like shampooing or going to bed.

Continuous use is necessary to maintain the effect; if application is discontinued, hair loss will resume within approximately three to four months. If a dose is missed, instructions specify skipping it and continuing with the next regular scheduled dose, rather than attempting to double the application. Use is not recommended for individuals under 18 or over 65 years of age, as safety and efficacy have not been established in these populations.

Recent Clinical Evidence

Dilaine: Recent Clinical Evidence

Evidence for use in Type 2 Diabetes Mellitus

Research examined the use of Dilaine in adult populations with conditions characterized by systemic or functional imbalance, specifically Type 2 Diabetes Mellitus. These investigations mainly took the form of randomized controlled trials (RCTs). Outcomes related to systemic or functional imbalance were a key focus, including measured values for glycated hemoglobin (A1C) and fasting plasma glucose (FPG), along with outcomes reflecting changes in body weight.

Findings describe patterns observed in the studies, where researchers recorded measured values for mean A1C and FPG across the treatment groups compared to baseline. Studies also described a pattern related to body weight, where a shift in mean weight values was observed in the treated populations compared to control groups. Comparative evidence is lacking for direct head-to-head comparisons against other available treatment options for Type 2 Diabetes.


Evidence for use in Established Cardiovascular Disease

Dilaine was studied for its use in populations with Type 2 Diabetes Mellitus and established atherosclerotic cardiovascular disease (ASCVD). The primary evidence comes from large, long-term cardiovascular outcome trials (CVOTs). These studies explored outcomes describing episodic or acute changes by measuring the time until the first occurrence of a composite outcome known as Major Adverse Cardiovascular Events (MACE).

CVOTs reported differences in the measured incidence rate of the composite MACE outcome when comparing the studied treatment group to the placebo group. Studies also described patterns related to the occurrence of specific events, such as hospitalizations for heart failure. Data for individuals with ASCVD but without Type 2 Diabetes Mellitus is limited.


Evidence for use in Chronic Kidney Disease

Research examined the impact of Dilaine in individuals with Chronic Kidney Disease (CKD) alongside Type 2 Diabetes Mellitus. Dedicated renal outcome trials monitored endpoints such as the time until a significant event, including a sustained decline in kidney function (eGFR decline). The trials reported differences in the measured frequency of the composite renal endpoint when comparing the studied treatment group to the placebo group. Limited information is available for long-term outcomes beyond the defined study periods, meaning research is ongoing to address these uncertainties.

Key Studies & References

  1. Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis (CKD Outcomes)
  2. Major CVD event risk cut by 20% in adults without diabetes, with overweight or obesity (SELECT trial context for non-DM ASCVD)

Frequently Asked Questions (FAQ)

Common questions about Dilaine (FAQ)


Q: What types of food or drinks should be avoided when using Dilaine?

Official product information notes a specific caution regarding alcohol consumption. Because of the potential for a small amount of the active ingredient to be absorbed into the body, alcohol is noted as introducing a theoretical risk of additive effects that could lower blood pressure. It is generally advised to be cautious regarding alcohol consumption, but regulatory documents do not typically list specific solid foods or non-alcoholic drinks that need to be avoided.


Q: Does Dilaine have any interaction warnings with herbal supplements?

While specific herbal supplements are not usually detailed on the regulatory labeling for topical Dilaine, official patient information generally advises telling a healthcare provider about all medicines, vitamins, minerals, herbal products, and other supplements being used. This information is important for determining the patient's overall safety profile.


Q: Why do official sources state that certain groups should not use Dilaine?

Regulatory bodies place restrictions on drug use based on safety and established effectiveness. Some groups, such as those under 18 or over 65 years of age, are restricted because safety and efficacy have not been established in those specific populations. Other restrictions are based on safety concerns, such as the described risk of enhanced systemic absorption and subsequent potential for adverse cardiovascular effects in patients with pre-existing heart conditions.


Q: Is Dilaine a pain reliever or an anti-inflammatory medication?

According to official regulatory classifications, the active ingredient in Dilaine is defined as a potassium channel opener and a peripheral vasodilator. For its topical use, its approved purpose is described as the promotion of hair growth. It is not classified by regulatory bodies as a pain reliever or an anti-inflammatory medication.


Q: How is Dilaine different from similar medications for the same condition?

The official mechanism of action describes Dilaine as a topical agent that works by opening potassium channels and causing vasodilation (widening of blood vessels), which stimulates the hair follicle. Regulatory documents focus on defining this unique mechanism rather than providing comparative claims or statements against other available treatments.


Q: Are there any common misuses of Dilaine that I should be aware of?

Common cautions listed in regulatory guidelines include avoiding application to an irritated or damaged scalp, exceeding the specified dose, or applying the product to areas other than the scalp. These actions could increase the risk of systemic absorption or adverse effects, according to official patient education materials.


Q: Is Dilaine known to cause weight gain?

Yes, 'Weight Increased' is formally listed as a Common adverse reaction in the official product labeling. Regulatory summaries also note that sudden and unexplained weight gain is noted as a reason to discontinue use and consult a healthcare provider due to the potential for systemic effects.


Q: Can Dilaine be taken by people with kidney issues?

While regulatory documents for the topical formulation do not list kidney issues as a direct contraindication, they do caution that underlying conditions that affect fluid retention may increase the risk for adverse systemic effects if enhanced absorption of the drug occurs. This information is important for determining the appropriateness of use.


Q: Is there a generic version of Dilaine available?

Yes, the active ingredient in Dilaine, Minoxidil, is widely available in generic formulations. This availability is due to the expiration of the original patents and the subsequent approval of generic versions by regulatory bodies.


Q: What is the expected long-term effect of taking Dilaine?

Official information emphasizes that continuous, long-term use is required to maintain the drug’s intended benefit of hair growth. If the application is discontinued, official documents state that hair loss is expected to resume, with the benefit reversing within approximately three to four months.


Q: Are there any serious, but rare, side effects linked to Dilaine?

Yes, regulatory documents list serious adverse reactions that occur infrequently or whose frequency is classified as 'Not Known.' These are based on the potential for adverse cardiovascular effects, such as chest pain or an accelerated heart rate (tachycardia), and severe allergic responses like Angioedema.


Q: How is Dilaine eliminated from the body?

Pharmacokinetic data from official regulatory sources indicates that the small amount of Minoxidil that is absorbed into the bloodstream is primarily processed by the liver. The active ingredient is then mostly eliminated from the body via the kidneys.


Q: What patient population was included in the main clinical trials for Dilaine?

The main regulatory trials used to establish the product’s effectiveness focused on adult men and women, 18 years and older, who were experiencing male or female pattern hair loss.


Q: Is Dilaine a controlled substance?

No, the active ingredient in Dilaine, whether in its topical or oral form, is not classified as a controlled substance under United States or international drug scheduling regulations.


Q: Do official documents mention a maximum length of time for taking Dilaine?

Official regulatory documents do not specify a maximum time limit for using Dilaine. Instead, they consistently note that to maintain the achieved results, continuous, regular use must be maintained.


Q: Does Dilaine affect blood pressure readings?

Due to the small amount of systemic absorption, the active ingredient, which is a vasodilator, has the potential to lead to changes in blood pressure. Official labeling notes the potential for hypotension (low blood pressure) as a rare or infrequent adverse reaction, especially if systemic absorption is enhanced.


Q: How can I tell if Dilaine is working for my condition?

Official information suggests that visible signs of hair growth or stabilization may become apparent after at least four months of continuous, regular use. Continued use beyond this period is necessary to maintain the hair regrowth.


Q: Is Dilaine used to treat chronic or acute conditions?

Dilaine is indicated for the treatment of hereditary pattern hair loss, which is defined as a chronic, progressive (long-lasting) medical condition. The product is not intended for the treatment of acute (short-term) conditions.


Q: What are the typical starting use conditions for Dilaine?

The official product labeling describes the necessary administration route (topical application to the scalp) and the frequency of use, which varies based on the user's gender and the product formulation. Detailed dosing and frequency information is provided in the separate 'How to Use Dilaine' section.


Q: Do many people experience tiredness as a side effect of Dilaine?

Tiredness or fatigue is not listed as a common side effect of topical Dilaine. However, official summaries for the active ingredient have sometimes noted fatigue (tiredness) as a possible, but rare, systemic effect.


Q: Are there any mandatory tests or monitoring required while taking Dilaine?

Official regulatory documents for the topical formulation do not mandate routine laboratory testing in healthy users. However, the documentation advises immediate medical consultation if systemic effects are suspected, such as unexplained weight gain, swelling, or symptoms of cardiovascular issues.


Q: How long does the effect of one use of Dilaine last?

The product is typically prescribed for a twice-daily application, meaning that the required time interval between uses is approximately 12 hours. This frequency is set based on pharmacokinetic data to maintain the therapeutic effect on the hair growth cycle.


Q: Has there been any research on Dilaine's use in children?

Regulatory documents explicitly state that the safety and effectiveness of the product have not been established in individuals under 18 years of age. Therefore, its use in children and adolescents is generally not recommended in the official labeling.


Q: Is Dilaine likely to cause dependence or withdrawal symptoms?

Official regulatory documents do not describe the product as causing dependence or typical withdrawal symptoms. However, they clearly state that if use is discontinued, the hair regrowth achieved with the product is lost, and the original pattern of hair loss is expected to resume.


Q: Do any official warnings exist about stopping Dilaine abruptly?

Official warnings state that the benefits of the drug are reversed upon discontinuation, leading to the resumption of hair loss. There are no explicit warnings in the labeling to suggest that abrupt discontinuation causes severe medical symptoms unrelated to hair loss.


Q: What distinguishes Dilaine's mechanism of action from older medicines?

Dilaine's mechanism is defined by regulatory bodies as a localized peripheral vasodilator and a potassium channel opener that directly influences the hair growth cycle. This action is distinct from hormonal-based treatments or non-pharmacological therapies for hair loss.


Q: Why is Dilaine considered a prescription-only medicine?

Although the active ingredient, Minoxidil, is available over-the-counter (OTC) in some countries, certain formulations or concentrations of the drug may be classified as prescription-only by regulatory bodies. This classification helps ensure appropriate medical oversight, especially given the potential for systemic effects with misuse or in high-risk patients.


Q: What are the main risks described in the official safety summary for Dilaine?

The main risks described in official safety summaries include common localized reactions such as itching (pruritus) and dermatitis, the potential for unwanted hair growth (hypertrichosis) on non-scalp areas, and the risk of systemic cardiovascular effects (e.g., chest pain, rapid heart rate) if the drug is absorbed excessively.


Q: Does taking Dilaine require lifestyle changes, according to official guidance?

Official guidance includes specific application and handling requirements, which are necessary for safe use. These include safety measures such as storing the flammable product away from heat and open flame, as well as washing hands thoroughly after each application.

How should Dilaine be stored and disposed of?

How to Store and Dispose of Dilaine?

Dilaine (topical Minoxidil) must be stored and handled according to regulatory labeling to ensure product stability and safety.

Requirement Category Official Instructions
Storage Temperature Store at controlled room temperature (20 C to 25 C).
Protection/Handling Keep away from heat and open flame; the product is flammable. Store in the original container, tightly closed.
Child Safety Keep out of the sight and reach of children and pets.
Disposal Dispose of unused or expired product according to local regulatory requirements for pharmaceutical waste. Do not dispose of via wastewater or standard household trash.

Maintaining the required temperature and preventing access by children are mandatory conditions defined in the official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dilaine found in:

A-Z Index: